Liver Cancer

NHS, HPFS Show Regular Aspirin Use Reduced Hepatocellular Carcinoma Risk

NHS, HPFS Show Regular Aspirin Use Reduced Hepatocellular Carcinoma Risk

By

An analysis of results from the NHS and the HPFS showed that regular use of aspirin — standard-dose 325-mg tablets — reduced hepacellular carcinoma in a dose-dependent manner.

Decreased Hepatocellular Carcinoma Tumor Burden With the Achievement of Hepatitis C Virus Sustained Virologic Response: Unlocking the Potential of T-cell-mediated Immunosurveillance

Decreased Hepatocellular Carcinoma Tumor Burden With the Achievement of Hepatitis C Virus Sustained Virologic Response: Unlocking the Potential of T-cell-mediated Immunosurveillance

[Journal of Hepatocellular Carcinoma] In this case series, the authors present procedure and treatment specifics for 2 patients with HCV who developed HCC, and discuss the potential role of DAA therapy and immunosurveillance.

Ado-trastuzumab Emtansine Effective in HER2 Amplified Non-breast, Non-gastric Cancers

Ado-trastuzumab Emtansine Effective in HER2 Amplified Non-breast, Non-gastric Cancers

By

Study results presented at 2018 ASCO Annual Meeting demonstrated effectiveness of ado-trastuzumab emtansine in non-breast non-gastric HER2-amplified cancers.

Individuals With Alcohol-Related Hepatocellular Carcinoma Have Reduced OS

Individuals With Alcohol-Related Hepatocellular Carcinoma Have Reduced OS

Patients with alcohol-related HCC displayed reduced OS when compared to patients with non-alcohol-related HCC.

Models of Intrahepatic Cholangiocarcinoma: Novel Tools and Therapeutic Applications

Models of Intrahepatic Cholangiocarcinoma: Novel Tools and Therapeutic Applications

[Gastrointestinal Cancer: Targets and Therapy] This review discusses novel tools and newer technologies that have been employed to address iCCA.

Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib

Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib

By

Results of the double-blind phase 3 CELESTIAL study, presented at the 2018 Gastrointestinal Cancers Symposium, demonstrated efficacy of cabozantinib in patients with HCC who were previously treated with sorafenib.

OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer

OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer

By

In a phase 3 study presented at the 2018 Gastrointestinal Cancers Symposium, researchers reported on OS outcomes with gemcitabine plus S-1 vs gemcitabine plus cisplatin in patients with advanced biliary tract cancer.

Indications for Cabozantinib in Advanced RCC Expanded to First-line Therapy

Indications for Cabozantinib in Advanced RCC Expanded to First-line Therapy

By

The FDA based its approval on data collected from the open-label, phase 2 CABOSUN study, for which researchers randomly assigned 157 patients with RCC to receive oral cabozantinib or sunitinib.

Married Status May Improve Survival Outcomes in Hepatocellular Carcinoma

Married Status May Improve Survival Outcomes in Hepatocellular Carcinoma

By

Recent studies have suggested that married patients experience a survival benefit for various cancers; marriage has been associated with earlier detection, undergoing treatment, as well as better economic status and social support.

Optimal Therapy for Patients with Hepatocellular Carcinoma and Resistance or Intolerance to Sorafenib: Challenges and Solutions

Optimal Therapy for Patients with Hepatocellular Carcinoma and Resistance or Intolerance to Sorafenib: Challenges and Solutions

[Journal of Hepatocellular Carcinoma] This research examines systemic therapies that can be considered in patients with sorafenib refractory hepatocellular carcinoma.

A Rare Case of Classical Hodgkin Lymphoma 10 Years After Liver Transplantation

A Rare Case of Classical Hodgkin Lymphoma 10 Years After Liver Transplantation

By

This case describes management of a 61-year-old male with a history of chronic liver diseases and COPD who developed a posttransplant lymphoproliferative disorder 10 years after a liver transplant.

Daily Aspirin Reduced Risk of HBV-Related Hepatocellular Carcinoma

Daily Aspirin Reduced Risk of HBV-Related Hepatocellular Carcinoma

By

Study presented at the AASLD The Liver Meeting 2017 demonstrated the effect of regular aspirin use on risk of hepatocellular carcinoma in patients with chronic HBV.

Reduced-Dose Sorafenib Effective and Economical in Hepatocellular Carcinoma

Reduced-Dose Sorafenib Effective and Economical in Hepatocellular Carcinoma

By

Reducing the initial dose of sorafenib was shown to have some benefits — such as reduced pill burden, lower costs, and decreased AE-related discontinuation rates — and OS was noninferior compared with the standard dose in patients with hepatocellular carcinoma.

Palliative Care Use Up for End-Stage Liver Disease

Palliative Care Use Up for End-Stage Liver Disease

Hispanic race and insurance coverage associated with lower referral to palliative care, data indicates.

Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities

Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities

A new report from ACS describes trends in liver cancer and the factors influencing the ongoing increase in incidence, particularly higher rates of HCV infection, obesity, and type 2 diabetes.

Liver Cancer the Fastest-Growing Cause of Cancer Deaths in United States

Liver Cancer the Fastest-Growing Cause of Cancer Deaths in United States

Liver cancer mortality has increased at a faster pace than other cancers in the United States, but substantial disparities exists in mortality rates for race/ethnicity and state of residence.

Durable Response Seen in Advanced HCC With Nivolumab

Durable Response Seen in Advanced HCC With Nivolumab

By

New data presented at the International Liver Congress 2017 suggest that nivolumab may produce long-term benefits in sorafenib-experienced patients with advanced HCC.

Research Shows iPS-ML/IFN-β Migrates to, Penetrate Liver Cancer Tumors

Research Shows iPS-ML/IFN-β Migrates to, Penetrate Liver Cancer Tumors

By

Decreased liver tumor growth and improved survival in a mouse model were noted after injecting iPS-ML/IFN-β.

A Single Institution Report of 19 Hepatocellular Carcinoma Patients With Bile Duct Tumor Thrombus

A Single Institution Report of 19 Hepatocellular Carcinoma Patients With Bile Duct Tumor Thrombus

[Journal of Hepatocellular Carcinoma] This research examines the outcomes of HCC patients with BDTT in a single institution.

Serum Liver Enzymes Serve as Prognostic Factors in Patients With Intrahepatic Cholangiocarcinoma

Serum Liver Enzymes Serve as Prognostic Factors in Patients With Intrahepatic Cholangiocarcinoma

This study examines the influences of liver enzymes on the overall survival in a number of patients with intrahepatic cholangiocarcinoma (ICC).

Cabozantinib Active in Hepatocellular Carcinoma

Cabozantinib Active in Hepatocellular Carcinoma

By

Treatment with cabozantinib was active and associated with manageable toxicities in patients with hepatocellular carcinoma.

Pediatric Hepatocellular Carcinoma: Challenges and Solutions

Pediatric Hepatocellular Carcinoma: Challenges and Solutions

[Journal of Hepatocellular Carcinoma] This research examines the medical challenges presented by pediatric hepatocellular carcinoma (HCC).

Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: The Evidence to Date

Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: The Evidence to Date

[Journal of Hepatocellular Carcinoma] This research examines tivantinib and its therapeutic profile in the management of hepatocellular carcinoma.

Prognostic role of pretreatment serum albumin in renal cell carcinoma: a systematic review and meta-analysis

Prognostic role of pretreatment serum albumin in renal cell carcinoma: a systematic review and meta-analysis

[OncoTargets and Therapy] This research examines the prognostic value of pretreatment serum albumin in RCC patients.

Hepatocellular Carcinoma: A Review

Hepatocellular Carcinoma: A Review

[Journal of Hepatocellular Carcinoma] This research examines the screening modalities, diagnosis, staging, and treatment of hepatocellular carcinoma (HCC), the most common primary liver malignancy.

Role of Regorafenib as Second-line Therapy and Landscape of Investigational Treatment Options in Advanced Hepatocellular Carcinoma

Role of Regorafenib as Second-line Therapy and Landscape of Investigational Treatment Options in Advanced Hepatocellular Carcinoma

[Journal of Hepatocellular Carcinoma] This review examines the multikinase inhibitors sorafenib and regorafenib, inhibitors of the MET pathway, and immunotherapeutics for the treatment of advanced hepatocellular carcinoma.

Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score

Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score

By

In patients with advanced HCC and a baseline αFP level of 400 ng/mL or more, a survival benefit with second-line ramucirumab therapy was observed for those with Child-Pugh scores of 5 and 6.

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

By

The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.

Comparative Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis

Comparative Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis

[Oncotargets and Therapy] This research evaluates the comparative efficacy and safety of axitinib and sorafenib for the treatment of metastatic renal cell carcinoma.

Premedication With Antiemetic Improves Length of Stay and Readmissions for a Liver Cancer Procedure

By

Including an antiemetic in the preprocedure medications for patients with liver cancer undergoing drug eluting bead chemoembolization (DEB TACE) can shorten hospital stays and reduce the chance for readmission due to complications.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs